Focused On-demand Library for Terminal nucleotidyltransferase 4B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8NDF8

UPID:

PAPD5_HUMAN

Alternative names:

Non-canonical poly(A) RNA polymerase PAPD5; PAP-associated domain-containing protein 5; Terminal guanylyltransferase; Terminal uridylyltransferase 3; Topoisomerase-related function protein 4-2

Alternative UPACC:

Q8NDF8; B4DV38; Q9NW67; Q9Y6C0

Background:

Terminal nucleotidyltransferase 4B, known as Non-canonical poly(A) RNA polymerase PAPD5, plays a crucial role in RNA stability and regulation. It catalyzes the addition of ATP and GTP to RNA 3' poly(A) tails, enhancing mRNA stabilization and participating in post-transcriptional quality control. This enzyme is pivotal in carbohydrate metabolism mRNA polyadenylation, histone mRNA degradation, and microRNA MIR21 regulation, showcasing its broad impact on gene expression.

Therapeutic significance:

Understanding the role of Terminal nucleotidyltransferase 4B could open doors to potential therapeutic strategies. Its involvement in mRNA stabilization, carbohydrate metabolism, and microRNA regulation presents it as a key target for modulating gene expression in various diseases.